22nd Century Group, Inc · NASDAQ:XXII
22nd Century — Q1 2025 Earnings Presentation
16 slides from 22nd Century's earnings presentation, May 13, 2025
Slide 1: Leading the Nicotine Harm Reduction Movement
Leading the Nicotine Harm Reduction Movement Investor Presentation May 2025 Company Confidential
Slide 2: Forward Looking Statements
Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements, including but not limited to our business outlook forward-looking statements typically contain terms such as “anticipate,”
Slide 3: At a Glance
At a Glance § NASDAQ – XXII – Headquartered in Mocksville, NC § Pure play tobacco company with a unique portfolio of brands Nicotine Harm Reduction Vertically Integrated Manufacturing Ø Proprietary VLN and Partner VLN products Ø Private label contract manufacturing Ø The only FDA authorized combusti
Slide 4: 2025 Growth Strategies
2025 Growth Strategies Relaunched VLN & Partner VLN in the Drive to Create a New Low Nicotine Category and Market with Updated Branding and Marketing Shelf Space in the Market § Expand retail footprint, add VLN Red and partner § Use VLN + partner brands to create a new brands with CMO Partners categ
Slide 5: Slide 5
Slide 6: Nicotine = Addiction
Nicotine = Addiction XXII MISSION: LEAD THE NICOTINE HARM REDUCTION MOVEMENT BY OFFERING A "CHOICE" § Nicotine is in the spotlight - $ Billions are being spent on nicotine harm awareness campaigns: Ø TV/Radio commercials – Undo.org, CDC, American Heart Assoc, others Ø Conferences Ø Healthcare restri
Slide 7: VLN Alignment with Zero/Low Proof Spirits
VLN Alignment with Zero/Low Proof Spirits § Compelling market dynamics – Consumers are choosing to break the paradigm Ø ‘Better for You’ Position Ø Above Premium Price Position (Tier 1), High Margin Delivery Ø Domestic and International Relevancy Ø Emotional/ Lifestyle Driven Marketing § Augments tr
Slide 8: VLN Products Plan
VLN Products Plan LEAD THE NICOTINE HARM REDUCTION MOVEMENT § The FIRST & ONLY low nicotine combustible product authorized by the FDA § Fully aligned with the FDA’s January 2025 Low Nicotine initiative § Develop the Low Nicotine Category (Very Low Nicotine Content) § Shifting from a novel idea to a
Slide 9: Launching Partner VLN: Building the Portfolio and Category
Launching Partner VLN: Building the Portfolio and Category § Leverage our CMO brands and distribution with VLN and Partner VLN – Build the VLN Portfolio § VLN Product Portfolio will grow in the market § Driving to create the Low Nicotine Content category as a stand alone SF VLN® PINNACLE VLN® VLN® P
Slide 10: Marketing VLN & Partner VLN
ee DAE 22N0 CENTURY GROUP Marketing VLN & Partner VLN TAKE CONTRO! FOBACES RE-IMAGINED
Slide 11: VLN Distribution
VLN® Distribution DIVERSE LIST OF U.S., RETAIL LOCATIONS CARRY VLN® PRODUCTS ACROSS BROAD GEOGRAPHY CURRENT DISTRIBUTION: § More than 5,100 retail stores across 26 states, including the three largest markets: Texas, California and Florida § Secured distribution with top national and regional tobacco
Slide 12: Smoker Friendly Black Label Cigarettes
Smoker Friendly Black Label Cigarettes !! N ew § Additive Free § Tobacco and Water Only § Premium American Blend Tobacco § Made in USA Many consumers want a Natural Cigarette price value alternative Style Comparable: American Spirit § Volume: over 25 million cartons annually § Brand Rank: #6 § Outle
Slide 13: R&D Drives Future Opportunities
R&D Drives Future Opportunities § Key Areas Of Focus: Ø The addition of 100mm VLN products to our lineup – Regular and Partner Ø Non-Combustible Low Nicotine Product Extensions Ø Partnership with NCSU on further low nicotine tobacco improvements Ø Low Nicotine Tobacco disease resistance Ø Other Low
Slide 14: TTM Condensed P&L
TTM Condensed P&L YTD 2025 Highlights: !"# !"# !"# !"# § Revenue improved in Q1 25 A BCDEA)G+AIGIJ .ELMENOEPA)G+AIGIJ #EQENOEPA)R+AIGIJ STPQ8A)G+AIGI9 with restoring key CMO A :E;EDCE<+ADEM B&&&&&&&&&&&&&&&&&&&&&&&&!"#$! B&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&'"#$( B&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&$")*) B&
Slide 15: Summary
Summary Ø Initiating profitable growth after successful turnaround Ø VLN® product strategy solidified and launched – new partner brands Ø VLN product portfolio to cross-sell into full market – Gradual growth through 2025 Ø Fully Aligned with the FDA's low nicotine mandate Ø Potential new Low Nicotin
Slide 16: www.xxiicentury.com Investor Relations
www.xxiicentury.com www.tryvln.com Investor Relations: Matt Kreps +1-214-597-8200 Mkreps@xxiicentury.com